The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes

References

• . American Heart Association. Heart Disease and Stroke Statistics—2008 Update. Dallas, TX: American Heart Association; 2008
   Google Scholar
• . Mehta RH, Montoye CK, Gallogly M, . Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287(10):1269–1276
   PubMed Web of Science ®Google Scholar
• . LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164(2):203–209
   PubMedGoogle Scholar
• . Duke Clinical Research Institute. 2005 CRUSADE 4th quarter results
   Google Scholar
• . Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2(12):e353
   Google Scholar
• . Newby LK, LaPointe NM, Chen AY, . Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–212
   PubMed Web of Science ®Google Scholar
• . Smith SC Jr, Allen J, Blair SN, . AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363–2372
   PubMed Web of Science ®Google Scholar
• . Anderson JL, Adams CD, Antman EM, . ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148–e304
   PubMed Web of Science ®Google Scholar
• . Grines CL, Bonow RO, Casey DE Jr, ; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49(6):734–739
   PubMed Web of Science ®Google Scholar
• . Parchure N, Brecker SJ. Management of acute coronary syndromes. Curr Opin Crit Care. 2002;8(3):230–235
   PubMedGoogle Scholar
• . Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc. 2006;81(5):641–652
   PubMedGoogle Scholar
• . Papathanasiou A, Goudevenos J, Tselepis AD. Resistance to aspirin and clopidogrel: possible mechanisms, laboratory investigation, and clinical significance. Hellenic J Cardiol. 2007;48(6):352–363
   PubMedGoogle Scholar
• . Merlini PA, Bauer KA, Oltrona L, . Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61–68
   PubMed Web of Science ®Google Scholar
• . Vickrey BG, Rector TS, Wickstrom SL, . Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke. 2002;33(4):901–906
   PubMedGoogle Scholar
• . Armstrong PW, Fu Y, Chang WC, . Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation. 1998;98(18):1860–1868
   PubMedGoogle Scholar
• . Capewell S, Murphy NF, MacIntyre K, . Short-term and long-term outcomes in 133,429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990–2000: population-based cohort study. Heart. 2006;92(11):1563–1570
   PubMedGoogle Scholar
• . Kassem-Moussa H, Mahaffey KW, Graffagnino C, ; SYMPHONY and 2nd SYMPHONY Investigators. Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. Am Heart J. 2004;148(3):439–446
   PubMed Web of Science ®Google Scholar
• . Budaj A, Flasinska K, Gore JM, ; GRACE Investigators. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation. 2005;111(24):3242–3247
   PubMed Web of Science ®Google Scholar
• . Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005;11(4):300–306
   PubMedGoogle Scholar
• . Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Morooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol. 2000;86(10):1057–1062
   PubMedGoogle Scholar
• . Cutlip DE, Baim DS, Ho KK, . Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103(15):1967–1971
   PubMed Web of Science ®Google Scholar
• . Holmes DR Jr, Kereiakes DJ, Laskey WK, . Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol. 2007; 50(2):109–118
   PubMedGoogle Scholar
• . King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, . 2007. Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117(2):261–295
   PubMedGoogle Scholar
• . Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86
   PubMed Web of Science ®Google Scholar
• . Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: An overview of antithrombotic therapy. BMJ. 2002;325(7367):762–765
   PubMed Web of Science ®Google Scholar
• . Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103(2):201–206
   PubMed Web of Science ®Google Scholar
• . Leon MB, Baim DS, Popma JJ, . A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339(23):1665–1671
   PubMed Web of Science ®Google Scholar
• . Bhatt DL, Bertrand ME, Berger PB, . Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39(1):9–14
   PubMed Web of Science ®Google Scholar
• . Paradiso-Hardy FL, Angelo CM, Lanctot KL, Cohen EA. Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ. 2000;163(11):1441–1448
   PubMed Web of Science ®Google Scholar
• . Smith SC Jr, Feldman TE, Hirshfeld JW Jr, ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113(7):e166–e286
   PubMed Web of Science ®Google Scholar
• . Chen ZM, Jiang LX, Chen YP, ; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–1621
   PubMed Web of Science ®Google Scholar
• . Mehta SR, Yusuf S, Peters RJ, ; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533
   PubMed Web of Science ®Google Scholar
• . Steinhubl SR, Berger PB, Mann JT 3rd, ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–2420
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502
   PubMed Web of Science ®Google Scholar
• . Sabatine MS, Cannon CP, Gibson CM, ; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–1189
   PubMed Web of Science ®Google Scholar
• . Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008;101(7):960–966
   PubMed Web of Science ®Google Scholar
• . Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–251
   PubMed Web of Science ®Google Scholar
• . Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003;91(9):1123–1125
   PubMed Web of Science ®Google Scholar
• . Brandt JT, Payne CD, Wiviott SD, . A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66.e69–e16
   Google Scholar
• . Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25( suppl 2):15–19
   PubMed Web of Science ®Google Scholar
• . Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost. 1999;25( suppl 2):3–8
   PubMedGoogle Scholar
• . Hochholzer W, Trenk D, Frundi D, . Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111(20):2560–2564
   PubMed Web of Science ®Google Scholar
• . Matetzky S, Shenkman B, Guetta V, . Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109(25):3171–3175
   PubMed Web of Science ®Google Scholar
• . Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157–1164
   PubMed Web of Science ®Google Scholar
• . Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154(2):221–231
   PubMed Web of Science ®Google Scholar
• . Jernberg T, Payne CD, Winters KJ, . Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166–1173
   PubMed Web of Science ®Google Scholar
• . Jakubowski JA, Matsushima N, Asai F, . A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007;63(4):421–430
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Trenk D, Frelinger AL, ; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923–2932
   PubMed Web of Science ®Google Scholar
• . Antman EM, Wiviott SD, Murphy SA, . Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028–2033
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353–1363
   PubMed Web of Science ®Google Scholar
• . Murphy SA, Antman EM, Wiviott SD, ; TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29(20):2473–2479
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015
   PubMed Web of Science ®Google Scholar
• . Biondi-Zoccai GG, Lotrionte M, Agostoni P, . A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667–2674
   PubMed Web of Science ®Google Scholar
• . Spertus JA, Kettelkamp R, Vance C, . Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803–2809
   PubMed Web of Science ®Google Scholar
• . Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet. 2006;7(3):163–173
   PubMedGoogle Scholar
• . Wiviott SD, Antman EM, Winters KJ, . Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111(25):3366–3373
   PubMed Web of Science ®Google Scholar